Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Partially Randomised Phase II Study to Investigate the Efficacy and Safety of BIBW 2992 in Patients With Metastatic Colorectal Cancer Who Never Received Prior Anti-EGFR (Epidermal Growth Factor Receptor) Treatment

NCT01152437 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01152437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01152437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Partially Randomised Phase II Study to Investigate the Efficacy and Safety of BIBW 2992 in Patients With Metastatic Colorectal Cancer Who Never Received Prior Anti-EGFR (Epidermal Growth Factor Receptor) Treatment
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2010
Completion date
Not reported
Enrollment
94 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms